The Trump administration’s decision to withdraw from the World Health Organization could complicate US access to health ...

J&J’s Spravato nasal spray received a label expansion on Tuesday, now approved as a standalone treatment for major depressive ...

A new FDA warning letter for French pharmaceutical company Sanofi cited a handful of issues at its biologics factory in ...

UnitedHealth's OptumRx to pass 100% of drug rebates to clients by 2028, but critics say GPO structure may still hide true ...

Stanford University professor Irv Weissman and a colleague published a paper that represented a new way to target some ...

Ascentage Pharma seeks $133M via US listing, markets olverembatinib in China with Takeda holding global rights. CEO Dajun ...

A father-and-son biotech with ties to Iceland and Philadelphia has put together a €26.5 million Series A to develop oral ...

Welcome back to the new and improved Endpoints Weekly! This week we’ll be recapping the JP Morgan Healthcare Conference, IRA ...

Spark co-founder Kathy High made a quiet return to eye disease drug development, becoming CEO of US-Swiss biotech RhyGaze ...

Sage Therapeutics has sued Biogen in Delaware court, one week after receiving a $469 million buyout offer from the larger neuroscience pharma company.